I started with moomoo, officially started investing for a year, and this week I went from 0.5 million initial capital to 7 million. The moomoo community has many talented individuals. However, the official team told me a few days ago that I am an important community user among the Chinese in australia. I have been following this before. $Tesla (TSLA.US)$ You can view my previous historical messages, always focusing on the few big opportunities I see within the US stock market.
Every day in the past year, I have been watching the market for several hours, knowing that diligence can bring wealth. I have no intention of stopping investing. Investing is a long-term topic, and I will continue to express opinions in the community. (Not investment advice, just for communication purposes. Adults should be responsible for their actions ☕️)

Hello Mooers! 
Today, in pre-market hours, many AI stocks are in the red. Microsoft ( $Microsoft (MSFT.US)$ ) and Meta Platforms ( $Meta Platforms (META.US)$ ) -3% to -4%, Apple ( $Apple (AAPL.US)$ ) around -1%, Super Micro Computer ( $Super Micro Computer (SMCI.US)$ ) -4% to -5%, NVIDIA ( $NVIDIA (NVDA.US)$ ), Amazon ( $Amazon (AMZN.US)$ ), Broadcom ( $Broadcom (AVGO.US)$ ) and Advanced Micro Devices ( $Advanced Micro Devices (AMD.US)$ ) -1% to -2%.
Would Mooers take ...

It was a worthwhile night, with daily income reaching a new high.
$NVIDIA (NVDA.US)$ $Nasdaq Composite Index (.IXIC.US)$ $E-mini NASDAQ 100 Futures(DEC4) (NQmain.US)$

$NVIDIA (NVDA.US)$
Excited on NVDA next week
+600% gain so far day trading mostly on Nvda

The whales ....
$Microsoft (MSFT.US)$ $Amazon (AMZN.US)$ $Alphabet-C (GOOG.US)$ $Apple (AAPL.US)$ $Meta Platforms (META.US)$ $NVIDIA (NVDA.US)$ $Visa (V.US)$ $JPMorgan (JPM.US)$ $Berkshire Hathaway-B (BRK.B.US)$ $MasterCard (MA.US)$ $UnitedHealth (UNH.US)$ $Johnson & Johnson (JNJ.US)$ $Exxon Mobil (XOM.US)$ $Eli Lilly and Co (LLY.US)$

$Johnson & Johnson (JNJ.US)$ has been under pressure due to talc lawsuits alleging its talc products cause ovarian cancer. In May, the company proposed a $6.5 billion settlement to resolve these claims. Despite this, J&J remains a top dividend stock with a 3.37% yield and has increased its dividend for 62 consecutive years. It has a forward P/E ratio of 13.79 makes it undervalued compared to the broader market. However, the firm does have more than forty new products in late stage clinical trials...